OBJECTIVES: Annual trivalent influenza vaccines (TIV) containing three influenza strains (A/H1N1, A/H3N2, and one B) have been recommended in Colombia since 2007. However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata) and difficulties in predicting which lineage will predominate in the next season have led to the development of quadrivalent influenza vaccines (QIV) including both B lineages. Our analysis evaluates the public health and economic benefits of using QIV versus TIV in Colombia from 2007 to 2014. METHODS: A static model published by Reed et al. in 2012 was adapted to Colombia and stratified by age group. In addition, B-lineage cross-protection was included based on published sources. We calculated the hypothetical impact of QIV compared with TIV over seven influenza seasons (2009 pandemic year excluded) using virologic circulation, vaccine coverage, vaccine effectiveness and attack rate. In absence of B-lineage distribution in Colombia for 2007-2013, Brazilian data were considered.  For influenza-related outcomes (outpatient visits, hospitalisations, deaths), two input sets were used. Influenza-related costs were estimated from societal perspective in Colombian pesos (0.00052 per US dollar in 2013). RESULTS: Over the 2007-2014 period, QIV would have prevented 27,957 influenza B cases compared with TIV, averting between 10,450 and 19,188 outpatient visits, between 492-7,549 hospitalisations and between 31-2,028 deaths. This translates into influenza-related avoided costs of between 1.7 and 12.5 billion pesos. In 2014, year with high B circulation and mismatch, QIV would have avoided 14,771 cases, 10,138 outpatient visits, 3,989 hospitalisations, 1,071 deaths and 6.6 billion pesos of influenza-related costs in the upper bound. CONCLUSIONS: The wider protection offered by QIV would reduce the number of influenza infections and its related complications, leading to influenza-related costs avoided. Herd effect was not taken into account, underestimating the benefits of QIV vaccination. More robust local data are needed to better assess benefits of QIV.